Steineck G, Strander H, Carbin B E, Borgström E, Wallin L, Achtnich U, Arvidsson A, Söderlund V, Näslund I, Esposti P L
Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden.
Acta Oncol. 1990;29(2):155-62. doi: 10.3109/02841869009126537.
In a randomized study of advanced renal cell carcinoma 60 patients were allocated to treatment with either recombinant interferon alpha-2a or medroxyprogesterone acetate. Correlation between the dose of interferon alpha-2a and plasma-concentration indicated linear kinetics. Survival was similar in the two treatment groups. Only one complete and one partial response were seen in the interferon group and only one complete response in the medroxyprogesterone group, indicating a low therapeutic potential of both interferon and medroxyprogesterone. Interferon influenced the serum liver enzyme levels; increased transaminases were seen in 17 patients treated with interferon but in only four patients in the medroxyprogesterone group. Two patients had very high serum liver-enzyme levels concomitant with intolerable tiredness, in both patients the symptoms disappeared and the enzymes normalized after discontinuation of the interferon treatment. Antibodies to interferon developed frequently in patients receiving high dose oligomeric interferon therapy but rarely in patients receiving low dose monomeric interferon treatment.
在一项针对晚期肾细胞癌的随机研究中，60例患者被分配接受重组干扰素α-2a或醋酸甲羟孕酮治疗。干扰素α-2a剂量与血浆浓度之间的相关性表明存在线性动力学。两个治疗组的生存率相似。干扰素组仅出现1例完全缓解和1例部分缓解，醋酸甲羟孕酮组仅出现1例完全缓解，这表明干扰素和醋酸甲羟孕酮的治疗潜力均较低。干扰素会影响血清肝酶水平；17例接受干扰素治疗的患者出现转氨酶升高，而醋酸甲羟孕酮组仅有4例患者出现这种情况。2例患者血清肝酶水平非常高，并伴有无法忍受的疲劳，在这两名患者中，停止干扰素治疗后症状消失且酶水平恢复正常。接受高剂量寡聚干扰素治疗的患者中经常产生干扰素抗体，而接受低剂量单体干扰素治疗的患者中很少产生。
